Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy

Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy

Mostra altre versioni (1)

<p><strong>Objective</strong> Drug‐resistant seizures are common in patients with leucine‐rich, glioma‐inactivated 1 (LGI1)‐IgG associated and contactin‐associated protein‐like 2 (CASPR2)‐IgG associated encephalitis. We performed the first randomized double‐blind placebo‐controlled...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Dubey, D, Britton, J, McKeon, A, Gadoth, A, Zekeridou, A, Chiriboga, SA, Devine, M, Cerhan, JH, Dunlay, K, Sagen, J, Ramberger, M, Waters, P, Irani, SR, Pittock, SJ
Natura:	Journal article
Lingua:	English
Pubblicazione:	Wiley 2019

Documenti analoghi

Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy
di: Dubey, D, et al.
Pubblicazione: (2019)

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
di: Binks, S, et al.
Pubblicazione: (2017)

Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis
di: Kelly, MJ, et al.
Pubblicazione: (2024)

CXCL13 levels in LGI1-and CASPR2-autoantibody syndromes
di: Michael, S, et al.
Pubblicazione: (2019)

Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2
di: Michael, S, et al.
Pubblicazione: (2020)

Distinct HLA associations of LGI1 and CASPR2-antibody diseases
di: Binks, S, et al.
Pubblicazione: (2018)

Immunotherapy responsive neuropathic pain associated with LGI1 and CASPR2 antibodies
di: Ramanathan, S, et al.
Pubblicazione: (2021)

Hippocampal epileptogenesis in LGI1, CASPR2 and GABABR antibodies: preliminary findings
di: Romoli, M, et al.
Pubblicazione: (2020)

Mechanisms of disease perpetuation and pathogenesis in autoantibody-mediated epilepsies with a focus on LGI1- and CASPR2-related syndromes
di: Michael, S
Pubblicazione: (2022)

The immunogenetics of LGI1- and CASPR2-antibody encephalitis: towards aetiology
di: Binks, S
Pubblicazione: (2022)

The distinct pattern of movement disorders in Caspr2 and LGI1 antibody associated autoimmune encephalitis
di: Goevert, F, et al.
Pubblicazione: (2019)

Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions
di: Steriade, C, et al.
Pubblicazione: (2020)

CXCL13 levels and autoantibody epitope specificities in LGI1-autoantibody syndromes
di: Michael, S, et al.
Pubblicazione: (2019)

LGI1-antibody associated epilepsy successfully treated in the outpatient setting
di: Uribe-San-Martín, R, et al.
Pubblicazione: (2020)

Intravenous immunoglobulin therapy.
di: Chapel, H
Pubblicazione: (1996)

Caspr2 antibodies in patients with thymomas.
di: Vincent, A, et al.
Pubblicazione: (2010)

Vgkc is dead: long live lgi1- and caspr2-antibodies. intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies
di: Lang, B, et al.
Pubblicazione: (2017)

New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin.
di: Marnane, M, et al.
Pubblicazione: (2008)

Home intravenous immunoglobulin therapy.
di: Chapel, H, et al.
Pubblicazione: (1988)

Intravenous immunoglobulin for the treatment of childhood encephalitis
di: Iro, M, et al.
Pubblicazione: (2017)

Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience
di: Kinsella, JA, et al.
Pubblicazione: (2018)

Hepatitis C and intravenous immunoglobulin - Concluding remarks
di: Chapel, H
Pubblicazione: (1996)

Hepatitis G virus in intravenous immunoglobulin - Reply
di: Healey, C, et al.
Pubblicazione: (1996)

Canomad presenting without ophthalmoplegia and responding to intravenous immunoglobulin.
di: Kam, C, et al.
Pubblicazione: (2011)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
di: Jang, Y, et al.
Pubblicazione: (2018)

Intravenous immunoglobulin in neurological disease: a specialist review.
di: Wiles, C, et al.
Pubblicazione: (2002)

Intravenous immunoglobulin and hepatitis C virus: the British episode.
di: Healey, C, et al.
Pubblicazione: (1996)

Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome.
di: Litzman, J, et al.
Pubblicazione: (1996)

Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?
di: Irani, SR, et al.
Pubblicazione: (2011)

Guidelines: Prescribing intravenous immunoglobulin: Summary of Department of Health guidelines
di: Provan, D, et al.
Pubblicazione: (2008)

OUTBREAK OF ACUTE HEPATITIS-C FOLLOWING INTRAVENOUS IMMUNOGLOBULIN THERAPY
di: Healey, C, et al.
Pubblicazione: (1994)

Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
di: Scheuerlein, P, et al.
Pubblicazione: (2018)

Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis.
di: Tofaris, G, et al.
Pubblicazione: (2012)

Placebo-controlled trial of intravenous immunoglobulin in ANCA-associated systemic vasculitis.
di: Jayne, D, et al.
Pubblicazione: (1999)

Intravenous immunoglobulin-induced haemolysis: A case report and review of the literature
di: Desborough, M, et al.
Pubblicazione: (2014)

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
di: Bjorkander, J, et al.
Pubblicazione: (2000)

Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature.
di: Desborough, M, et al.
Pubblicazione: (2014)

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.
di: Jayne, DR, et al.
Pubblicazione: (2000)

Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review.
di: Dicato, M, et al.
Pubblicazione: (1991)

Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms
di: Ramberger, M, et al.
Pubblicazione: (2020)